SEATTLE, Feb. 25, 2026 /PRNewswire/ -- Valant, the leading provider of behavioral health EHR software, today announced expanded capabilities for its AI-powered clinical documentation tool, AI Notes ...
Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line ...
Women remain underrepresented in senior medical leadership, despite making up the majority of the NHS workforce. As the Royal College of Physicians (RCP) marks International Women’s Day (IWD) and ...
Phase III study will be "sufficient and pivotal for registration in the U.S." Kiniksa Pharmaceuticals ( KNSA 2.70%) ...
Medicine is supposed to be precise, clinical, and strictly professional, but sometimes, it takes an unexpectedly hilarious turn. In the middle of documenting symptoms and treatment plans, a perfectly ...
Discover the impact of digital pathology on drug discovery and biomarker research this International Women’s Day with Dr ...
Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with ...
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript March 5, 2026 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.3 EPS, expectations were $-1.01. Operator: Thank you for ...
Ottawa Citizen on MSN
Canada's Drug Agency says new Alzheimer's drug should not be publicly funded
A decision by Canada’s Drug Agency will make it more difficult for Canadians to access a drug shown to slow Alzheimer’s disease in some people, says an Ottawa cognitive neurologist and researcher.
Roboplasty Centre was already powered with three globally recognized robotic platforms — VELYS Robotic System, MAKO Robotic System, and CUVIS Robotic System. Despite this advanced infrastructure, the ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
ConfirmMDx: An epigenetic test used to help identify patients at increased risk for aggressive prostate cancer following a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results